Ramon Alemany Bonastre

This inventor holds 7 USPTO granted patents and 4 published patent applications, plus 4 CIPO patents and 3 EPO patents. Top assignees: Institut Catala D Oncologia, Fundacio Institut D'investigacio Biomedica De Bellvitge (Idibell), Institut Catala D'oncologia (Ico). Active years: 2008-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ramon Alemany Bonastre. Retrieved from https://idiyas.com/inventor/ramon-alemany-bonastre

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 7 (Patent Applications = 4)

% Patents Active = 85.7

CIPO Patents = 4

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 40(Granted Patents)

Location History:

Barcelona, ES (2008 - 2018)
Castelldefels, ES (2019)
Castelldefels-Barcelona, ES (2020 - 2023)

Company Filing History:

3 out of 3

Institut Catala D Oncologia

patents

2 out of 13

Fundacio Institut D'investigacio Biomedica De Bellvitge (Idibell)

patents

2 out of 4

Institut Catala D'oncologia (Ico)

Fundacio Institut D'investigacio Biomedica De Bellvitge

patent

6. 1 out of 1

Fundació Institut D'lnvestigació Biomedica De Bellvitge (Í Dibell)

patent

7. 1 out of 65

Oncolytics Biotech Inc.

patents

where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12129280 - Oncolytic adenoviruses for treating cancer (2024-10-29),

2. 11578104 - Adenovirus comprising an albumin-binding moiety (2023-02-14),

3. 10604549 - Adenovirus comprising an albumin-binding moiety (2020-03-31),

4. 10316065 - Oncolytic adenoviruses for treating cancer (2019-06-11),

5. 10016470 - Oncolytic adenoviruses for cancer treatment (2018-07-10),

6. 8974777 - Adenovirus with mutations in the endoplasmic reticulum retention domain of the E3-19K protein and their use in cancer treatment (2015-03-10),

7. 7344711 - Use of adenoviruses mutated in the VA genes for cancer treatment (2008-03-18),

Title: Ramon Alemany Bonastre: Innovator in Cancer Treatment

Introduction

Ramon Alemany Bonastre is a notable inventor based in Castelldefels, Spain. He has made significant contributions to the field of cancer treatment through his innovative work on oncolytic adenoviruses. With a total of five patents to his name, his research focuses on enhancing the efficacy of cancer therapies.

Latest Patents

One of Alemany Bonastre's latest patents involves an oncolytic adenovirus that incorporates a sequence encoding a hyaluronidase enzyme within its genome. This innovative adenovirus is designed to spread more efficiently within tumor masses, thereby increasing the oncolytic effect. By injecting this oncolytic adenovirus endovenously, significant tumor volume regressions can be achieved. This invention holds promise for the treatment of various cancers and pre-malignant states.

Career Highlights

Throughout his career, Ramon Alemany Bonastre has worked with esteemed institutions such as the Catalan Institute of Oncology. His research has been pivotal in advancing the understanding and treatment of cancer through innovative viral therapies.

Collaborations

Alemany Bonastre has collaborated with notable colleagues, including Manel Maria Cascallo Piqueras and Sònia Guedan Carrió. These partnerships have contributed to the development of groundbreaking cancer treatments.

Conclusion

Ramon Alemany Bonastre's work in the field of oncolytic adenoviruses represents a significant advancement in cancer therapy. His innovative approach and dedication to research continue to inspire progress in the fight against cancer.

Profile summary based on public USPTO records.